Please login to the form below

Getting it Right First Time: Building a Value-Based Contract Strategy

In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.

The promise of innovative technologies is significant and is welcomed globally. The prospect of new therapies that could save and transform the lives of those living with severe conditions is eagerly anticipated, not only by patients but by all those within healthcare systems.

Less welcome are the associated challenges of a less stable evidence base at launch and potential high costs of these new technologies and therapies. Payers fear that so many therapies are being developed at such a fast pace that they cannot afford to introduce them into the system, despite their promised clinical benefit. Companies face uncertainty around reimbursement and the expectations for post-authorisation real world data generation. Patients also face the real possibility that treatments will be developed that could help them but that they are unable to access.

Affordability and the acceptance of real-world evidence are hot topics without clear solutions. Increasingly, innovative, value-based contracts (VBCs) are being agreed, with payers and companies looking at ways to bring therapies to patients. VBCs can focus on ensuring access, driving uptake, or both. They can address concerns about the evidence base, particularly when it comes to longer term outcomes in chronic or progressive conditions. They can also address barriers in infrastructure, capacity, diagnosis and affordability. The more complex the VBC, the more difficult it can be to agree, requiring significant resource from both companies and payers to develop. As they become more frequent, particularly for innovative therapies, we anticipate a shift from payers towards standardising VBCs. However, this does not mean one approach for all.

Recently we have seen successful launches of innovative therapies, but they can often take a long time and uptake may be slower than anticipated, something we have seen even with the highly effective Zolgensma for Spinal Muscular Atrophy. As VBCs become more common, companies are generally taking one of three approaches: a single global VBC strategy regardless of market, a region-by-region strategy or a country-by-country approach.

None of these approaches fully consider the external environment across countries, or the broader landscape. Instead, we recognise that there are commonalities between countries across the world that may not readily map onto geographical regions – Europe alone will require more than one type of VBC to address different payer preferences.

To develop global strategies and the tools that will best support local teams achieve success, global market access teams need to understand the external environment across countries, as well as the broader landscape, how this is likely to change and how the company can influence any such change. By mapping out the similarities and differences between markets, companies can move to more tailored access approaches that recognise the commonalities and differences between markets, regardless of geography.

Global teams will succeed where they are able to identify a small number of market archetypes in terms of their readiness to agree VBCs and the types of agreement that will fit well within their healthcare systems, their policy priorities, the current provision in the specific therapeutic area and capacity to deliver the new therapy.

This will enable global teams to identify a limited number of approaches to VBCs for an asset and the markets where they are most likely to succeed. Global teams can provide parameters for local teams to work within, to select the right VBC strategy first time, increasing the chance of securing a VBC that works for all stakeholders and brings products to the patients who need them.

7th March 2022


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications
Getting it Right First Time: Building a Value-Based Contract Strategy
In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.
Hanover Communications
The role of pharma in breaking through the backlog
As health systems emerge from the pandemic, and attention turns to the backlog of patients waiting for treatment, how can the pharmaceutical industry position itself as part of the solution? In his latest blog, Hanover Health’s Alexander Davies looks to answer the following questions – big pharma was there for the world when it needed vaccines in record-breaking time, can it find the innovations that we need now to clear through the queue of people waiting for treatment? Can it partner with health systems to speed up access, improve patient outcomes and reduce the burden on healthcare professionals? And, if it did so, what are the opportunities for its reputation?
Hanover Communications
Cardiovascular disease: The scale of the challenge
Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with cardiovascular diseases (CVD) are identified, diagnosed, and managed across England. In his latest blog, Hanover Health’s Mark MacDonald asks – what does this data tell us about the impact CVD is having on our collective health, how much are health inequalities a factor, and where are the opportunities for the system to collectively do better to prevent disease, disability, and death?
Hanover Communications
Cancer: Beyond the Backlog
With the recent performance of Cancer Waiting Times the worst on record, and predictions of thousands of ‘missing’ cancer patients that have yet to enter the system, Hanover’s Health’s Emma Greenwood asks – how do we get back to that transformation agenda and move beyond the backlog?
Hanover Communications